AAAAAA

   
Results: 1-14 |
Results: 14
Effects of statins on biomarkers of bone metabolism: A randomised trial
Authors: Stein, EA Farnier, M Waldstreicher, J Mercuri, M
Citation: Ea. Stein et al., Effects of statins on biomarkers of bone metabolism: A randomised trial, NUTR MET CA, 11(2), 2001, pp. 84-87
Hyperlipidemia in the elderly
Authors: Farnier, M
Citation: M. Farnier, Hyperlipidemia in the elderly, PRESSE MED, 30(19), 2001, pp. 957-963
The AFSSAPS recommendations for good practice: Therapeutic management of patients with dyslipidemia.
Authors: Ducimetiere, P Signeyrole, D Giral, P Hoog-Labouret, N Amarenco, P Chanu, B Chauvenet, M Coletti, M Dallongeville, J Durlach, V Kawka, G Krempf, M Leroux, G Mlika-Cabanne, N Monnier, L Paillard, F Rostoker, G Sicard, D Verny, C Voiriot, P Acquart, B Alquier, G Ankri, J Badoc, G Basdevant, A Belmin, J Berthezene, F Beucler, I Blanc, F Broustet, JP Bruckert, E Brun, JM Castaigne, A Charpentier, JM Andre, MC Cogneau, J Demeaux, JL Denolle, T Desson, JF Drahi, E Drouin, P Dumel, F Emmerich, J Farnier, M Fontbonne, A Forette, B Gambert, P Gautier, JC Guillausseau, PJ Hommel, M Janowski, M Le Goaziou, MF Lievre, M Le Quere, M Leys, D Marechaud, R Mas, JL Menard, J Michel, JM Mounier-Vehier, F Mottier, D Passa, P Pinel, JF Puel, J Raccah, D Renou, P Ribier, A Schlienger, JL Thomas, D Vallee, JP Veyssier-Belot, C Bouvenot, G Abadie, E Alexandre, JM Belorgey-Bismut, C Bergmann, JF Camelli, B Caulin, C Costagliola, D Denis, C Dupuis, B Fleurette, F Guillevin, L Hoog-Labouret, N Paintaud, G Rauss, A Poynard, T Rostoker, G Wong, O
Citation: P. Ducimetiere et al., The AFSSAPS recommendations for good practice: Therapeutic management of patients with dyslipidemia., J MAL VASC, 26(2), 2001, pp. 105-110
Management of dyslipidaemia diagnosed in general practice in France - The PRAGMA study
Authors: Amouyel, P Farnier, M Lyon, G Siest, G Mortier, N Amiot, N Duprat-Lomon, I
Citation: P. Amouyel et al., Management of dyslipidaemia diagnosed in general practice in France - The PRAGMA study, ARCH MAL C, 94(10), 2001, pp. 1045-1053
Obesity and cardio-vascular risk
Authors: Krempf, M Farnier, M
Citation: M. Krempf et M. Farnier, Obesity and cardio-vascular risk, ANN ENDOCR, 62(4), 2001, pp. S23-S29
Efficacy and safety of micronised fenofibrate in a randomised double-blindstudy comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia
Authors: Krempf, M Rohmer, V Farnier, M Issa-Sayegh, M Corda, C Sirugue, I Gerlinger, C Masseyeff-Elbaz, MF
Citation: M. Krempf et al., Efficacy and safety of micronised fenofibrate in a randomised double-blindstudy comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia, DIABETE MET, 26(3), 2000, pp. 184-191
Action of atorvastatin in combined hyperlipidemia - Preferential reductionof cholesteryl ester transfer from HDL to VLDL1 particles
Authors: Guerin, M Lassel, TS Le Goff, W Farnier, M Chapman, MJ
Citation: M. Guerin et al., Action of atorvastatin in combined hyperlipidemia - Preferential reductionof cholesteryl ester transfer from HDL to VLDL1 particles, ART THROM V, 20(1), 2000, pp. 189-197
Autosomal dominant type IIa hypercholesterolemia: evaluation of the respective contributions of LDLR and APOB gene defects as well as a third major group of defects
Authors: Saint-Jore, B Varret, M Dachet, C Rabes, JP Devillers, M Erlich, D Blanchard, P Krempf, M Mathe, D Chanu, B Jacotot, B Farnier, M Bonaiti-Pellie, C Junien, C Boileau, C
Citation: B. Saint-jore et al., Autosomal dominant type IIa hypercholesterolemia: evaluation of the respective contributions of LDLR and APOB gene defects as well as a third major group of defects, EUR J HUM G, 8(8), 2000, pp. 621-630
Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia
Authors: Farnier, M Dejager, S
Citation: M. Farnier et S. Dejager, Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia, AM J CARD, 85(1), 2000, pp. 53-57
Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA
Authors: Desrumaux, C Athias, A Bessede, G Verges, B Farnier, M Persegol, L Gambert, P Lagrost, L
Citation: C. Desrumaux et al., Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA, ART THROM V, 19(2), 1999, pp. 266-275
Hyperlipidemia: role of different statins
Authors: Farnier, M
Citation: M. Farnier, Hyperlipidemia: role of different statins, PRESSE MED, 28(36), 1999, pp. 2002-2010
Efficacy and safety of 300 mu g and 400 mu g cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study
Authors: Hanefeld, M Deslypere, JP Ose, L Durrington, PN Farnier, M Schmage, N
Citation: M. Hanefeld et al., Efficacy and safety of 300 mu g and 400 mu g cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study, J INT MED R, 27(3), 1999, pp. 115-129
Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin
Authors: Lagrost, L Athias, A Lemort, N Richard, JL Desrumaux, C Chatenet-Duchene, L Courtois, M Farnier, M Jacotot, B Braschi, S Gambert, P
Citation: L. Lagrost et al., Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin, ATHEROSCLER, 143(2), 1999, pp. 415-425
A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32
Authors: Varret, M Rabes, JP Saint-Jore, B Cenarro, A Marinoni, JC Civeira, F Devillers, M Krempf, M Coulon, M Thiart, R Kotze, MJ Schmidt, H Buzzi, JC Kostner, GM Bertolini, S Pocovi, M Rosa, A Farnier, M Martinez, M Junien, C Boileau, C
Citation: M. Varret et al., A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32, AM J HU GEN, 64(5), 1999, pp. 1378-1387
Risultati: 1-14 |